VANCOUVER, Jan. 9, 2017 /CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced it has changed its corporate name to Sierra […]

Read On ›

ProNAi Initiates ‘Brighton’ Phase II Trial of PNT2258 in Patients with Richter’s Transformation

VANCOUVER, Oct. 29, 2015 /CNW/ – ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced it has enrolled the first patient […]

Read On ›

ProNAi Therapeutics Announces Closing of IPO and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

VANCOUVER, July 21, 2015 /CNW/ – ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the closing of its initial public […]

Read On ›

ProNAi Therapeutics Announces Pricing of Initial Public Offering

VANCOUVER, July 15, 2015 /CNW/ – ProNAi Therapeutics, Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the pricing of its initial public offering […]

Read On ›

ProNAi to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Vancouver, BC and Plymouth, MI – January 12, 2015. ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi® platform, today announced that […]

Read On ›

ProNAi Therapeutics Strengthens Senior Management Team to Advance DNAi®-based Oncology Therapeutics

Vancouver, BC, Canada and Plymouth, MI, USA – October 22, 2014. ProNAi Therapeutics Inc., a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi® platform, today announced […]

Read On ›

ProNAi Therapeutics, Inc. Names New President and Chief Executive Officer

Plymouth, Ml-September 3, 2014. ProNAi Therapeutics, Inc., a developer of novel nucleic acid therapeutics, announces the appointment Nick Glover, Ph.D. as President and Chief Executive Officer. The company’s previous CEO, Mina Sooch, will be leaving […]

Read On ›

ProNAi Therapeutics Raises $59.5 Million Series D Financing

Plymouth, MI—April 21, 2014. ProNAi Therapeutics, Inc., a developer of novel nucleic acid therapeutics, announced the closing of an oversubscribed $59.5 million Series D financing. The round was led by Vivo Capital of Palo Alto, […]

Read On ›